IBO

Company Overview — What Does IMPACT BIOMEDICAL INC. Do?

Impact Biomedical, Inc. (“IBIO”) currently is a holding company operating mainly through our majority owned subsidiary, Global BioLife, Inc., which was incorporated on April 14, 2017. The Company is committed to both funding research and developing intellectual property portfolio. We currently focus on research in three main areas: (i) development of a universal therapeutic drug platform; (ii) a new sugar substitute; and (iii) a multi-use fragrance. IBIO discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships. Currently, our operations are conducted, and our assets are owned through our principal subsidiaries: (i) Global BioLife, Inc. (“Global BioLife”), which was incorporated on April 14, 2017, (ii) Impact BioLife Science (“Impact BioLife”), which was incorporated on August 28, 2020, (iii) Global BioMedical, Inc. (“Global BioMedical”), which was incorporated on April 18, 2017, and (iv) Sweet Sense, Inc. (“Sweet Sense”), which was incorporated on April 30, 2018. By leveraging technology and new science with strategic partnerships, we provide advances in biopharmaceuticals and over the counter direct to consumer wellness offerings, and drug discovery for the prevention, inhibition, and treatment of neurological, oncology and immuno-related diseases. In addition to our existing efforts, we continually search for and evaluate other potential new offerings to add to our portfolio. Our business model includes partnering and potentially direct sales for commercialization and distribution. Potential licensors and development partners include pharmaceutical, consumer packaged goods companies and others, who would commercialize IBIO technologies in exchange for milestone, and royalty licensing payments. Below is a list of our principal subsidiaries: . Impact BioLife Science, Inc.; . Global Biomedical, Inc.; . Global BioLife, Inc.; and . Sweet Sense, Inc. Impact BioLife Science, Inc. We are the sole owner of the outstanding equity of Impact BioLife Science, Inc. Global Biomedical, Inc. We own 90.9% of Global Biomedical, Inc.’s outstanding equity. Global BioLife, Inc. Through our majority owned subsidiary Global Biomedical, Inc., we own 81.8% of the outstanding equity of Global BioLife, Inc. Sweet Sense, Inc. We are the owner of 95.5% of the outstanding equity of Sweet Sense. Impact BioMedical Inc. is a Nevada corporation and was incorporated in October 2018. Our principal executive offices are located at 1400 Broadfield Blvd., Suite 130, Houston, Texas. IMPACT BIOMEDICAL INC. (IBO) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Frank D. Heuszel, headquartered in HOUSTON, Texas. With a market capitalization of $66M, IBO is one of the notable companies in the Healthcare sector.

IMPACT BIOMEDICAL INC. (IBO) Stock Rating — Reduce (April 2026)

As of April 2026, IMPACT BIOMEDICAL INC. receives a Reduce rating with a composite score of 25.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.IBO ranks #3,420 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, IMPACT BIOMEDICAL INC. ranks #526 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

IBO Stock Price and 52-Week Range

IMPACT BIOMEDICAL INC. (IBO) currently trades at $0.69. The stock lost $0.02 (3.1%) in the most recent trading session. The 52-week high for IBO is $6.17, which means the stock is currently trading -88.9% from its annual peak. The 52-week low is $0.36, putting the stock 89.9% above its annual trough. Recent trading volume was 69K shares, suggesting relatively thin trading activity.

Is IBO Overvalued or Undervalued? — Valuation Analysis

IMPACT BIOMEDICAL INC. (IBO) carries a value factor score of 26/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.64x, versus the sector average of 2.75x.

At current multiples, IMPACT BIOMEDICAL INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

IMPACT BIOMEDICAL INC. Profitability — ROE, Margins, and Quality Score

IMPACT BIOMEDICAL INC. (IBO) earns a quality factor score of 27/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -82.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -73.9% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

IBO Debt, Balance Sheet, and Financial Health

IMPACT BIOMEDICAL INC. has a debt-to-equity ratio of 12.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 0.35x, which may signal near-term liquidity tightness.

IBO has a beta of -1.52, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for IMPACT BIOMEDICAL INC. is 29/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

IMPACT BIOMEDICAL INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, IMPACT BIOMEDICAL INC. reported revenue of $0 and earnings per share (EPS) of $-0.38. Net income for the quarter was $-13M. Operating income came in at $-4M.

In FY 2025, IMPACT BIOMEDICAL INC. reported revenue of N/A and earnings per share (EPS) of $-0.38. Net income for the quarter was $-12M. Operating income came in at $-4M.

In Q3 2025, IMPACT BIOMEDICAL INC. reported revenue of N/A and earnings per share (EPS) of $-0.12. Net income for the quarter was $-1M. Operating income came in at $-948,000.

In Q2 2025, IMPACT BIOMEDICAL INC. reported revenue of N/A and earnings per share (EPS) of $-1.18. Net income for the quarter was $-14M. Operating income came in at $-1M.

Over the past 8 quarters, IMPACT BIOMEDICAL INC. has experienced revenue contraction from $0 to $0. Investors analyzing IBO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

IBO Dividend Yield and Income Analysis

IMPACT BIOMEDICAL INC. (IBO) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

IBO Momentum and Technical Analysis Profile

IMPACT BIOMEDICAL INC. (IBO) has a momentum factor score of 26/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 18/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

IBO vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, IMPACT BIOMEDICAL INC. (IBO) ranks #526 out of 838 stocks based on the Blank Capital composite score. This places IBO in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing IBO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full IBO vs S&P 500 (SPY) comparison to assess how IMPACT BIOMEDICAL INC. stacks up against the broader market across all factor dimensions.

IBO Next Earnings Date

No upcoming earnings date has been announced for IMPACT BIOMEDICAL INC. (IBO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy IBO? — Investment Thesis Summary

The quantitative profile for IMPACT BIOMEDICAL INC. suggests caution. The quality score of 27/100 flags below-average profitability. The value score of 26/100 indicates premium valuation. Momentum is weak at 26/100, a headwind for near-term performance. High volatility (stability score 29/100) increases portfolio risk.

In summary, IMPACT BIOMEDICAL INC. (IBO) earns a Reduce rating with a composite score of 25.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on IBO stock.

Related Resources for IBO Investors

Explore more research and tools: IBO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare IBO head-to-head with peers: IBO vs AZN, IBO vs SLGL, IBO vs VMD.